Molecular Profile Detail

To all our CKB CORE users, don’t miss the latest new features now available! Register for a free CORE account here and then login for access. Feel free to contact us at ckbsupport@genomenon.com if you have any questions!

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

Profile Name	IDH1 R132X
Gene Variant Detail	IDH1 R132X (unknown)
Relevant Treatment Approaches	IDH Inhibitor (Pan) IDH1 Inhibitor

Filtering

Case insensitive filtering will display rows if any text in any cell matches the filter term
Use simple literal full or partial string matches
Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
Click on any column header arrows to sort by that column
Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Clinical Trial	Phase	Therapies	Title	Recruitment Status	Covered Countries	Other Countries
NCT02746081	Phase I	BAY1436032	Phase I Study of BAY1436032 in IDH1-mutant Advanced Solid Tumors	Completed	USA \| DNK \| DEU	1
NCT06707493	Phase II	Ivosidenib	Ivosidenib As Post-HSCT Maintenance for AML	Not yet recruiting	USA	0
NCT04655391	Phase I	Glasdegib Glasdegib + Ivosidenib Bosutinib + Glasdegib Gilteritinib + Glasdegib Decitabine + Glasdegib + Venetoclax Enasidenib + Glasdegib	Glasdegib-Based Treatment Combinations for the Treatment of Patients With Relapsed Acute Myeloid Leukemia Who Have Undergone Hematopoietic Cell Transplantation	Withdrawn	USA	0
NCT03471260	Phase Ib/II	Azacitidine + Ivosidenib + Venetoclax Ivosidenib + Venetoclax	Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malignancies	Recruiting	USA	0
NCT04521686	Phase I	LY3410738	Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations	Active, not recruiting	USA \| FRA \| ESP \| AUS	5
NCT03839771	Phase III	Ivosidenib Enasidenib	A Study of Ivosidenib or Enasidenib in Combination With Induction Therapy and Consolidation Therapy, Followed by Maintenance Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myedysplastic Syndrome EB2, With an IDH1 or IDH2 Mutation, Respectively, Eligible for Intensive Chemotherapy (HOVON150AML)	Active, not recruiting	SWE \| NOR \| NLD \| LUX \| LTU \| IRL \| FRA \| FIN \| EST \| ESP \| DEU \| CHE \| BEL \| AUT \| AUS	0
NCT03564821	Phase I	Ivosidenib	IDH1 Inhibition Using Ivosidenib as Maintenance Therapy for IDH1-mutant Myeloid Neoplasms Following Allogeneic Stem Cell Transplantation	Completed	USA	0
NCT02074839	Phase I	Ivosidenib	Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation	Recruiting	USA \| FRA	0
NCT02719574	Phase I	Cytarabine + Olutasidenib Olutasidenib Azacitidine + Olutasidenib	Open-label Study of FT-2102 With or Without Azacitidine or Cytarabine in Patients With AML or MDS With an IDH1 Mutation	Completed	USA \| ITA \| GBR \| FRA \| ESP \| DEU \| CAN \| AUS	1
NCT04250051	Phase I	Cytarabine + Filgrastim + Fludarabine + Ivosidenib Ivosidenib	Ivosidenib and Combination Chemotherapy for the Treatment of IDH1 Mutant Relapsed or Refractory Acute Myeloid Leukemia	Active, not recruiting	USA	0
NCT03914742	Phase Ib/II	Pamiparib + Temozolomide	BGB-290 and Temozolomide in Treating Patients With Recurrent Gliomas With IDH1/2 Mutations	Completed	USA	0
NCT03684811	Phase Ib/II	Cisplatin + Gemcitabine + Olutasidenib Azacitidine + Olutasidenib Olutasidenib Nivolumab + Olutasidenib	A Study of FT-2102 in Patients With Advanced Solid Tumors and Gliomas With an IDH1 Mutation	Completed	USA \| GBR \| FRA \| ESP \| AUS	1
NCT06782542	Phase II	Azacitidine + Olutasidenib + Venetoclax	Olutasidenib, Venetoclax, and Azacitidine in IDH1 Mutated Newly Diagnosed Acute Myeloid Leukemia Patients Eligible for Intensive Induction Chemotherapy (OLUVENAZA)	Not yet recruiting	USA	0
NCT02381886	Phase I	IDH305	A Study of IDH305 in Patients With Advanced Malignancies That Harbor IDH1R132 Mutations	Active, not recruiting	USA \| NLD \| ESP \| DEU \| CAN \| BEL \| AUS	1
NCT04603001	Phase I	LY3410738	Study of Oral LY3410738 in Patients With Advanced Hematologic Malignancies With IDH1 or IDH2 Mutations	Active, not recruiting	USA \| ISR \| FRA \| FIN \| ESP \| DEU \| CAN \| BEL \| AUS	3
NCT03528642	Phase I	Radiotherapy + Telaglenastat + Temozolomide	Telaglenastat With Radiation Therapy and Temozolomide in Treating Patients With IDH-Mutated Diffuse Astrocytoma or Anaplastic Astrocytoma	Active, not recruiting	USA	0
NCT04493164	Phase II	CPX-351 + Ivosidenib Ivosidenib	CPX-351 and Ivosidenib for the Treatment of IDH1 Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome	Recruiting	USA	0
NCT02977689	Phase II	IDH305	Trial of IDH305 in IDH1 Mutant Grade II or III Glioma	Withdrawn	USA	0
NCT04013880	Phase Ib/II	Decitabine and Cedazuridine + Olutasidenib	ASTX727 and FT-2102 in Treating IDH1-Mutated Recurrent/Refractory Myelodysplastic Syndrome or Acute Myeloid Leukemia	Withdrawn		0